Voigt Andrew, Ezzeddine Rana, Barrington William, Obiaha-Ngwu Ogundu, Ganz Leonard I, London Barry, Saba Samir
Cardiovascular Institute, University of Pittsburgh, Pennsylvania, USA.
J Am Coll Cardiol. 2004 Aug 18;44(4):855-8. doi: 10.1016/j.jacc.2004.05.053.
We analyzed the incidence of implantable cardioverter-defibrillator (ICD) therapy in survivors of cardiac arrest (CA) in the U.S. from 1996 through 2001.
Cardiac arrest is a class I indication for ICD therapy. The current patterns of ICD utilization in survivors of CA have not been fully examined.
We searched a representative sample of all hospital discharges for patients admitted with the primary diagnosis of CA who survived to hospital discharge. Patients with a concomitant diagnosis of acute myocardial infarction or previous ICD in situ were excluded.
From 1996 to 2001, 113,262 patients were admitted for CA. Of those, 63,745 (56.3%) did not survive to hospital discharge. Of the remaining 49,517 patients, 30.7% received an ICD before discharge, with a gradual increase in implantation rates from 1996 (23.6%) to 2001 (46.3%). Using logistic regression for the years 2000 and 2001, patients who were discharged without an ICD were older (odds ratio [OR] 0.93 for every 10-year increase in age, p < 0.001), more likely to be African American (OR 0.19, p < 0.001), and more likely to be admitted to a smaller hospital (OR 2.24 for each additional 100 beds, p < 0.001). These predictors were independent of other co-morbid illnesses.
Although they are increasing, the rates of ICD therapy after CA remain very low. There are gross discrepancies by race. At a time when newer indications for ICD implantation are emerging, efforts should be focused on identifying the causes of this underutilization and discrepancies in survivors of CA.
我们分析了1996年至2001年美国心脏骤停(CA)幸存者接受植入式心脏复律除颤器(ICD)治疗的发生率。
心脏骤停是ICD治疗的I类适应证。目前CA幸存者中ICD的使用模式尚未得到充分研究。
我们在所有医院出院病例的代表性样本中,查找以CA为主要诊断入院且存活至出院的患者。排除伴有急性心肌梗死诊断或既往原位植入ICD的患者。
1996年至2001年,113262例患者因CA入院。其中,63745例(56.3%)未存活至出院。在其余49517例患者中,30.7%在出院前接受了ICD治疗,植入率从1996年的23.6%逐渐上升至2001年的46.3%。使用2000年和2001年的逻辑回归分析,未接受ICD而出院的患者年龄较大(年龄每增加10岁,优势比[OR]为0.93,p<0.001),更可能是非裔美国人(OR为0.19,p<0.001),且更可能入住规模较小的医院(每增加100张床位,OR为2.24,p<0.001)。这些预测因素独立于其他合并疾病。
尽管CA后ICD治疗率在上升,但仍然很低。存在明显的种族差异。在ICD植入新适应证不断涌现的时期,应致力于找出CA幸存者中这种使用不足和差异的原因。